Humanigen Inc

Humanigen — Investor Presentation (June 2018)

20 slides from Humanigen's investor presentation, Jun 5, 2018

  1. Slide 1: Enhancing T-Cell Therapies in Oncology

    Enhancing T-Cell Therapies in Oncology OTCQB: HGENwww.humanigen.com 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding fu

  3. Slide 3: Strategic Focus – Enhancing T-Cell Therapies in Oncology

    Strategic Focus – Enhancing T-Cell Therapies in Oncology Short, Medium and Long-Term Growth Drivers: 3 Focus on CAR-T- induced AEs to prevent onset/severity of neurotoxicitySevere patient risk factor, also impacting clinical trial holds, commercial uptake and hospital resources Focus on optimizing C

  4. Slide 4: Big Commercial, Partnering Universe in T-Cell Therapy

    Big Commercial, Partnering Universe in T-Cell Therapy 4

  5. Slide 5: Experienced, Execution-Focused Leadership and Board; Extensive CAR-T and Immuno-Oncology Expertise

    Experienced, Execution-Focused Leadership and Board; Extensive CAR-T and Immuno-Oncology Expertise Cameron Durrant, MD, MBACEOPharma and serial biotech execPharmacia/Pfizer, J+J in the US; Merck, GSK in EuropeBiotech Exec Chairman, Chairman, CEO, CFO Greg Jester, CPA CFO Decades of financial, operat

  6. Slide 6: 'Achilles Heel' of CAR-T: Neurotoxicity, Cytokine Release Syndrome

    ‘Achilles Heel’ of CAR-T: Neurotoxicity (NT), Cytokine Release Syndrome (CRS) Up to 87% with NT and 94% with CRS*One-third/one-half of patients have grade ≥3 NT, potential ICU admissionSeveral deaths *Package insert for KYMRIAH, YESCARTA www.cellculturedish.com 6

  7. Slide 7: Myeloid and CAR-T Cells' Increase in Brain Associated with NT

    Myeloid and CAR-T Cells’ Increase in Brain Associated with NT 7 Cell Populations (in CSF) NE Grade 0-2 (n=15)Median cells/mL(Q1, Q3) NE Grade > 3 (N=10)Median cells/mL(Q1, Q3) NE Grade > 3/Grade 0-2Ratio CD45+ (leukocytes) 166 (18, 1504) 570 (170, 1700) 3.4 CD14+ (myeloid cells) 18 (11, 436) 306 (12

  8. Slide 8: GM-CSF from T Cells Triggers Central Nervous System Damage

    Zhao, et al. GM-CSF-Commanding CNS Invasion. Immunity 46. Feb 21, 2017 GM-CSF production by T cells starts expansion of monocyte-derived cells (MdC) and CNS inflammationMdCs produce IL-1 and ROS, cross BBB and activate microgliaMicroglia secrete CCL2, recruit CCR2-expressing inflammatory MdCs into t

  9. Slide 9: Fever and Elevated MCP-1 (CCL2) Predict Severe CRS, NT

    Patients with fever and very high MCP-1 generally develop severe CRS and NT within 36 hours of infusionMCP-1 regulated by GM-CSF Gust, Turtle, et al. Cancer Discovery. Oct 2017, DOI: 10.1158/2159-8290.CD-17-0698 9 Fever and Elevated MCP-1 (CCL2) Predict Severe CRS, NT B-ALL CLL NHL

  10. Slide 10: Evidence Shows Strong GM-CSF Link to Neurotoxicity

    Evidence Shows Strong GM-CSF Link to Neurotoxicity Elevated GM-CSF associated with grade > 3 NTIL-2 only other cytokine with this association Published clinical association in Zuma-1 trial Locke, Neelapu et al, AACR 2017 10

  11. Slide 11: Scientific Rationale Points to GM-CSF Trigger to CAR-T A/Es

    Sentman, et al. www.jimmunol.org/content/197/12/4674.long; Coxford, et al. Immunity 2015 (43)510-514; Ishii, et al. Blood 2016 128:3358; Teachey, et al. Cancer Discov. 2016 June ; 6(6): 664–679. doi:10.1158/2159-8290.CD-16-0040; Lee, et al. Blood 2016 124:2:188; David M. Barrett et al. Blood 2016;12

  12. Slide 12: Lenzilumab: First-in-Class, Anti-GM-CSF Monoclonal Antibody

    Lenzilumab: First-in-Class, Anti-GM-CSF Monoclonal Antibody Lenzilumab Binds to and neutralizes circulating GM-CSF Safety and tolerability well established from one Phase I, two Phase II studies Compelling safety and tolerability profile in over 100 patientsEfficacy signals in Phase II eosinophilic

  13. Slide 13: In Vivo Preclinical Data: Positive Survival, Proliferation

    More robust proliferation after treatment with lenzilumab in vivo (~5x) Lenzilumab does not impede CAR-T cell function in vivo in the absence of PBMCsSurvival similar for CAR-T + control and CAR-T + lenzilumab In Vivo Preclinical Data: Positive Survival, Proliferation 13 Kenderian, S: Presentation a

  14. Slide 14: Lenzilumab CAR-T Development Plan Has Top KOL Support

    Lenzilumab CAR-T Development Plan Has Top KOL Support 14 Top KOLs understand GM-CSF as target KOLs proactively offered to study neurotoxicity prevention Lenzilumab pivotal study as prophylactic therapy prior to CAR-T infusion to prevent NT with YESCARTA, expected start 2H 2018 at MD Anderson (with l

  15. Slide 15: HGEN Scientific Advisory Board Input From Top KOLs at Leading Centers

    HGEN Scientific Advisory Board Input From Top KOLs at Leading Centers 15 Massachusetts General Hospital, HarvardMoffittOlivia Newton-John Cancer Research InstituteMemorial Sloan Kettering Cancer CenterCHOPU PennDana Farber Cancer Institute HarvardMayo ClinicSeattle Children’sUniversity of FloridaMD

  16. Slide 16: Framing Lenzilumab's Extensive Value Potential

    Framing Lenzilumab’s Extensive Value Potential GM-CSF neutralization reduces MDSC IDO and PD-L1 expression Lenzilumab as ‘booster’ of CAR-T: in vivo cell expansion data One-third to a half of patients require ICU stay Prophylactic lenzilumab to prevent onset of CAR-T potentially life-threatening sid

  17. Slide 17: Ifabotuzumab: First-in-Class, EphA3 Monoclonal Antibody

    Ifabotuzumab: First-in-Class, EphA3 Monoclonal Antibody Targets Eph receptor A3 Phase I bio-imaging study in glioblastoma multiforme (GBM), promising initial resultsCAR being designed Developed an Antibody Drug Conjugate EphA3 Receptor Ifabotuzumab INTRACELLULAR Inhibition of cell positioning, survi

  18. Slide 18: Monoclonal Antibody Pipeline

    Monoclonal Antibody Pipeline Preclinical Phase I Phase II Phase III BLA Lenzilumab(anti-GM-CSF mAb) Prophylaxis CAR-T-induced serious A/Es, potential improved efficacy (CAR-T companion/booster) CMML (monotherapy in salvage patients - fully enrolled) Ifabotuzumab(anti-EphA3 mAb) GBM (monotherapy in s

  19. Slide 19: Vigorous Partnering Activity in this Field

    Vigorous Partnering Activity in this Field 19

  20. Slide 20: Summary

    Summary Top KOLs back scientific rationale for lenzilumab starting pivotal trials Lenzilumab has potential to make CAR-T safer, more effective and a more routine out-patient procedure Not enough ICU beds for numbers of patients necessary to hit analyst forecasts; hospital reimbursement additional ga

Humanigen — Investor Presentation (June 2018) on 6ix